Neumora Therapeutics, Inc. (NMRA)

Neumora Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-252.09	-243.79	-235.93	-130.9	-237.31	-99.27
Depreciation & Amortization	0.49	0.63	0.67	0.59	0.54	0.11
Asset Writedown & Restructuring Costs	-	-	63.9	13	157	69.86
Loss (Gain) From Sale of Investments	-4.59	-5.72	-3.74	-0.71	-	-
Stock-Based Compensation	36.34	39.99	17.24	8.3	4.27	1.68
Other Operating Activities	3.79	3.31	3.48	1.77	1.04	3.99
Change in Accounts Payable	-0.54	2.87	-0.58	-1.25	-0.76	-4.67
Change in Other Net Operating Assets	20.48	19.76	-8.32	-5.7	-0.2	1.55
Operating Cash Flow	-195.68	-182.94	-163.28	-114.9	-75.42	-26.76
Capital Expenditures	0.78	-	-0.12	-0.51	-0.82	-1.3
Cash Acquisitions	-	-	-	-	-	2.81
Sale (Purchase) of Intangibles	-0.78	-0.78	-4.59	-13	-	-
Investment in Securities	132.66	-69.78	69.09	-154.5	-	-
Other Investing Activities	-	-	-	-	-	-12.75
Investing Cash Flow	132.75	-70.56	64.39	-168.01	-0.82	-11.24
Long-Term Debt Issued	-	-	-	-	-	55.91
Net Debt Issued (Repaid)	18.4	-	-	-	-	55.91
Issuance of Common Stock	17.16	21.6	236.23	2.66	3.47	3.19
Repurchase of Common Stock	-	-	-0.49	-	-	-0
Other Financing Activities	-	-	-3.8	-0.92	-1.21	-0.9
Financing Cash Flow	35.56	21.6	231.94	115.74	293.51	230.1
Net Cash Flow	-27.37	-231.89	133.05	-167.17	217.27	192.1
Free Cash Flow	-194.9	-182.94	-163.4	-115.41	-76.24	-28.06
Free Cash Flow Per Share	-1.21	-1.15	-2.51	-4.24	-3.48	-2.16
Cash Income Tax Paid	0.47	0.47	-	-	-	-
Levered Free Cash Flow	-105.69	-100.7	-111.24	-93.02	-37.08	-
Unlevered Free Cash Flow	-105.69	-100.7	-111.24	-93.02	-37.08	-
Change in Working Capital	19.95	22.64	-8.9	-6.95	-0.96	-3.12

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q